Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BASEL, MARCH 29, 2026  NOVARTIS TODAY ANNOUNCED FINAL TWO-YEAR RESULTS FROM THE PHASE III APPLAUSEIGAN STUDY OF FABHALTA (IPTACOPAN) IN IGA NEPHROPATHY (IGAN). FABHALTA DEMONSTRATED A STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL IMPROVEMENT IN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) SLOPE, A KEY MARKER OF KIDNEY FUNCTION, COMPARED WITH PLACEBO1. FABHALTA CONSISTENTLY OUTPERFORMED PLACEBO ACROSS KEY KIDNEY OUTCOMES OVER TWO YEARS, DEMONSTRATING A SLOWING OF DISEASE PROGRESSION AND THE POTENTIAL TO PRESERVE KIDNEY FUNCTION IN IGAN1. THE RESULTS WERE PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE AND SIMULTANEOUSLY PRESENTED AS LATEBREAKING DATA AT THE 2026 WORLD CONGRESS OF NEPHROLOGY (WCN).

NOVARTIS IGAN DATA IN NEW ENGLAND JOURNAL OF MEDICINE SHOW FABHALTA SLOWED KIDNEY FUNCTION DECLINE BY 49.3%

 ACQUISITION BRINGS TOGETHER EXCELLERGY'S DIFFERENTIATED TRIFUNCTIONAL ALLERGIC EFFECTOR CELL RESPONSE INHIBITORS (ECRIS) AND THE DEVELOPMENT EXPERTISE OF NOVARTIS, WITH A TOTAL POTENTIAL TRANSACTION VALUE OF UP TO $2 BILLION   EXL-111 IS A POTENTIALLY FIRST-IN-CLASS ALLERGIC TRIFUNCTIONAL ECRI TARGETING THE IGE AXIS AND IS CURRENTLY IN PHASE 1 DEVELOPMENT  PALO ALTO, CALIF., MARCH 27, 2026 (GLOBE NEWSWIRE) -- EXCELLERGY, A BIOTECHNOLOGY COMPANY DEVELOPING A NOVEL CLASS OF ALLERGY THERAPEUTICS, TODAY ANNOUNCED IT WILL BE ACQUIRED BY NOVARTIS IN A TRANSACTION WITH A TOTAL POTENTIAL VALUE OF UP TO $2 BILLION IN UPFRONT AND MILESTONE PAYMENTS.

EXCELLERGY TO BE ACQUIRED BY NOVARTIS FOR UP TO USD 2 BILLION TO ADVANCE POTENTIALLY FIRST-IN-CLASS TRIFUNCTIONAL EFFECTOR CELL RESPONSE INHIBITORS

-PROPOSED ACQUISITION STRENGTHENS NOVARTIS IMMUNOLOGY STRATEGY IN FOOD ALLERGY AND OTHER IGE-DRIVEN DISEASES   - LEAD ASSET EXL-111 BUILDS ON PROVEN IGE BIOLOGY WITH A DIFFERENTIATED MECHANISM DESIGNED TO DISSOCIATE RECEPTOR-BOUND IGE AND DRIVE FASTER, DEEPER PATHWAY SUPPRESSION   - EXL-111 WOULD COMPLEMENT EXISTING NOVARTIS PORTFOLIO IN ALLERGY WITH POTENTIAL TO IMPROVE BOTH SYMPTOM CONTROL AND CONVENIENCE  BASEL, MARCH 27, 2026  NOVARTIS TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT TO ACQUIRE EXCELLERGY, INC., A PRIVATE BIOTECH COMPANY DEVELOPING NEXT-GENERATION ANTI-IGE THERAPIES FOR IGE-DRIVEN DISEASES. THE PROPOSED ACQUISITION ADDS EXL-111, A HALF-LIFE EXTENDED, HIGH-AFFINITY ANTI-IGE ANTIBODY IN PHASE 1. THE ACQUISITION BUILDS ON DEEP NOVARTIS EXPERTISE IN IGE BIOLOGY AND A LONG-STANDING PRESENCE IN ALLERGIC DISEASE. EXL-111 IS DESIGNED AS A NEXT-GENERATION EXTENSION OF VALIDATED BIOLOGY ESTABLISHED BY ANTI-IGE THERAPY, WITH THE POTENTIAL TO COMPLEMENT THE NOVARTIS EXISTING ALLERGY PORTFOLIO ACROSS A RANGE OF ALLERGIC CONDITIONS AND PATIENT SETTINGS.EXCELLERGY ADDS A DIFFERENTIATED NEXT-GENERATION ANTI-IGE PROGRAM THAT BUILDS ON BIOLOGY NOVARTIS KNOWS WELL, SUPPORTED BY PRECLINICAL EVIDENCE AND EARLY CLINICAL PHARMACOKINETIC DATA, SAID FIONA MARSHALL, PRESIDENT OF BIOMEDICAL RESEARCH AT NOVARTIS. EXL-111 IS DESIGNED TO GO BEYOND CONVENTIONAL ANTI-IGE THERAPY, WITH THE POTENTIAL TO DELIVER FASTER AND DEEPER SUPPRESSION OF IGE SIGNALING AS WELL AS IMPROVED SYMPTOM CONTROL. THIS PROPOSED ACQUISITION STRENGTHENS OUR ALLERGY PORTFOLIO AND REFLECTS OUR STRATEGY OF ADVANCING INNOVATIVE BOLD SCIENCE TO BRING MEANINGFUL ADDITIONAL BENEFITS TO PATIENTS.IGE IS A CENTRAL DRIVER OF MULTIPLE ALLERGIC DISEASES. UNLIKE CONVENTIONAL ANTI-IGE APPROACHES, EXL-111 IS DESIGNED TO DISSOCIATE RECEPTOR-BOUND IGE WITH THE POTENTIAL TO DRIVE FASTER AND DEEPER FC EPSILON RI ALPHA (FCRI) DOWNREGULATION. PRECLINICAL STUDIES AND EARLY HUMAN PHARMACOKINETIC DATA FROM ONGOING PHASE 

NOVARTIS AGREES TO ACQUIRE EXCELLERGY, INC., BUILDING ON ALLERGY LEADERSHIP WITH NEXT-GENERATION ANTI-IGE INNOVATION

BASEL, MARCH 23, 2026  NOVARTIS WILL PRESENT DATA FROM MORE THAN 20 ABSTRACTS FROM ITS GROWING IMMUNOLOGY PORTFOLIO AT THIS YEAR'S AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING.

NOVARTIS PRESENTS NEW DATA ON EARLY SYMPTOM RELIEF AND LONG-TERM CONTROL IN COMPLEX SKIN DISEASES AT AAD 2026

WILMINGTON, DEL.--(BUSINESS WIRE)--SYNNOVATION THERAPEUTICS, LLC (SYNNOVATION), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY WITH A DIVERSE PIPELINE OF NOVEL SMALL-MOLECULE TARGETED THERAPIES IN ONCOLOGY AND IMMUNOLOGY TODAY ANNOUNCED A DEFINITIVE AGREEMENT FOR NOVARTIS TO ACQUIRE PIKAVATION THERAPEUTICS, INC. (PIKAVATION) AND ITS PORTFOLIO OF PI3K INHIBITOR PROGRAMS, INCLUDING SNV4818. PIKAVATION IS A WHOLLY-OWNED SUBSIDIARY OF SYNNOVATION. SNV4818 IS A POTENTIALLY BEST-IN-CLASS PAN-MUTANT SELE.

NOVARTIS TO ACQUIRE SYNNOVATION THERAPEUTICS' PAN-MUTANT SELECTIVE PI3K INHIBITOR PROGRAM

BASEL, MARCH 20, 2026  NOVARTIS TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT WITH SYNNOVATION THERAPEUTICS, LLC TO ACQUIRE SNV4818, A PAN-MUTANTSELECTIVE PI3K INHIBITOR, EXPLORING A NEXT-GENERATION APPROACH FOR THE TREATMENT OF PATIENTS WITH HR+/HER2- BREAST CANCER AND POTENTIALLY OTHER SOLID TUMOR INDICATIONS.

NOVARTIS AGREES TO ACQUIRE A PAN-MUTANT-SELECTIVE PI3K INHIBITOR, STRENGTHENING ITS BREAST CANCER PIPELINE

BASEL, MARCH 13, 2026  NOVARTIS ANNOUNCED TODAY THAT COSENTYX(SECUKINUMAB) RECEIVED US FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL FOR TREATINGPEDIATRICPATIENTS12 YEARS AND OLDER WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA (HS),MAKING IT THE ONLY IL-17A INHIBITOR FOR THIS POPULATION1.THE APPROVAL OF A DISTINCT BIOLOGIC OPTION FORPEDIATRIC PATIENTSLIVINGWITH HSALLOWS TREATMENT TO BE TAILORED TO THE INDIVIDUAL AND ESTABLISHES COSENTYXASA MEANINGFUL ADDITION TO THE TREATMENT LANDSCAPE1-13.

NOVARTIS COSENTYX RECEIVES FDA APPROVAL FOR PEDIATRIC PATIENTS AGED 12+ WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

BASEL, MARCH 6, 2026  NOVARTIS SHAREHOLDERS TODAY AGREED TO THE BOARD OF DIRECTORS' RECOMMENDATIONS FOR ALL PROPOSED RESOLUTIONS AT THE COMPANY'S ANNUAL GENERAL MEETING (AGM). A TOTAL OF 1 554 SHAREHOLDERS WERE PRESENT AT THE MEETING HELD IN BASEL, REPRESENTING APPROXIMATELY 59.15% OF THE ISSUED SHARES OF NOVARTIS. WITH A DIVIDEND INCREASE OF 5.7% TO CHF 3.70 PER SHARE, SHAREHOLDERS APPROVED THE 29TH CONSECUTIVE INCREASE, RESULTING IN A DIVIDEND YIELD OF 3.0%. PAYMENT OF THE 2025 DIVIDEND WILL BE MADE FROM MARCH 12, 2026. ELECTION OF A NEW MEMBER OF THE BOARD OF DIRECTORS SHAREHOLDERS HAVE RE-ELECTED GIOVANNI CAFORIO AS MEMBER OF THE BOARD OF DIRECTORS AND BOARD CHAIR. IN ADDITION, SHAREHOLDERS ELECTED CHARLES SWANTON AS NEW MEMBER OF THE BOARD OF DIRECTORS. DANIEL HOCHSTRASSER DID NOT STAND FOR RE-ELECTION. ALL OTHER MEMBERS OF THE BOARD OF DIRECTORS HAVE BEEN RE-ELECTED. ALL ELECTIONS AND RE-ELECTIONS PERTAIN TO A TERM LASTING UNTIL THE COMPLETION OF THE NEXT AGM. SHAREHOLDERS ALSO RE-ELECTED ALL CURRENT MEMBERS OF THE COMPENSATION COMMITTEE AND ELECTED ELIZABETH MCNALLY AS NEW MEMBER OF THE COMPENSATION COMMITTEE, EACH UNTIL THE END OF THE NEXT AGM. WITH HIS RE-ELECTION, SIMON MORONEY REMAINS CHAIR OF THE COMMITTEE IN LINE WITH THE DESIGNATION FROM THE BOARD OF DIRECTORS. REDUCTION OF SHARE CAPITAL SHAREHOLDERS APPROVED THE PROPOSAL BY THE BOARD OF DIRECTORS TO CANCEL 77602358 SHARES AND TO REDUCE THE SHARE CAPITAL ACCORDINGLY BY CHF38025155.42 (FROM CHF1035086714.83 TO CHF 997061559.41). COMPENSATION FOR THE BOARD OF DIRECTORS AND THE EXECUTIVE COMMITTEE IN TWO SEPARATE BINDING VOTES, SHAREHOLDERS APPROVED THE TOTAL MAXIMUM AGGREGATE AMOUNT OF COMPENSATION FOR THE BOARD OF DIRECTORS, COVERING THE PERIOD FROM THE 2026 AGM TO THE 2027 AGM, AND THE TOTAL MAXIMUM AGGREGATE AMOUNT OF COMPENSATION FOR THE EXECUTIVE COMMITTEE FOR THE 2027 FINANCIAL YEAR. SHAREHOLDERS FURTHER ENDORSED THE 2025 COMPENSATION REPORT IN AN ADVISORY VOTE. RESOLUTIONS FOR A DETAILED LISTING O

NOVARTIS SHAREHOLDERS APPROVE ALL RESOLUTIONS PROPOSED BY THE BOARD OF DIRECTORS AT THE 2026 ANNUAL GENERAL MEETING

ADDS AVIDITY'S DIFFERENTIATED MUSCLE-DIRECTED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOC) PLATFORM AND THREE LATE-STAGE PROGRAMS TO INDUSTRY-LEADING NEUROMUSCULAR PIPELINE POTENTIALLY UNLOCKS MULTI-BILLION-DOLLAR OPPORTUNITIES WITH PLANNED PRODUCT LAUNCHES BEFORE 2030 STRENGTHENS LATE-STAGE PIPELINE TO FURTHER SUPPORT 2025-2030 NET SALES CAGR OF 5-6% CC AND MID TO LONG TERM GROWTH OUTLOOK BASEL, FEBRUARY 27, 2026 -- NOVARTIS AG (NYSE: NVS) TODAY ANNOUNCED THAT IT HAS SUCCESSFULLY COMPLETED ITS ACQUISITION OF AVIDITY BIOSCIENCES, INC. (AVIDITY). WITH THE COMPLETION OF THE ACQUISITION, AVIDITY IS NOW AN INDIRECT, WHOLLY OWNED SUBSIDIARY OF NOVARTIS.

NOVARTIS SUCCESSFULLY COMPLETES ACQUISITION OF AVIDITY BIOSCIENCES, STRENGTHENING LATE-STAGE NEUROSCIENCE PIPELINE AND ADVANCING XRNA STRATEGY

BASEL, FEBRUARY 27, 2026  NOVARTIS ANNOUNCED TODAY THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) HAS ADOPTED A POSITIVE OPINION RECOMMENDING MARKETING AUTHORIZATION FOR REMIBRUTINIB. THE OPINION SUPPORTS ITS USE AS AN ORAL TREATMENT FOR CHRONIC SPONTANEOUS URTICARIA (CSU) IN ADULT PATIENTS WITH INADEQUATE RESPONSE TO H1ANTIHISTAMINE TREATMENT. THE INTRODUCTION OF REMIBRUTINIB REPRESENTS A MAJOR ADVANCEMENT, PROVIDING CLINICIANS WITH AN ORAL BRUTON'S TYROSINE KINASE INHIBITOR (BTKI) TREATMENT, WITH IMPROVEMENTS IN SYMPTOMS OBSERVED AS EARLY AS WEEK1, SAID PROF. DR. MED. MARTIN METZ, DEPUTY DIRECTOR, INSTITUTE OF ALLERGOLOGY, CHARIT UNIVERSITTSMEDIZIN BERLIN. CSU CONTINUES TO IMPOSE A SUBSTANTIAL UNMET MEDICAL NEED, AS MANY PATIENTS STRUGGLE TO ACHIEVE ADEQUATE DISEASE CONTROL WITH CURRENTLY AVAILABLE THERAPIES. THE POSITIVE CHMP OPINION IS SUPPORTED BY RESULTS FROM THE PIVOTAL REMIX-1 AND REMIX-2 PHASE III TRIALS. REMIBRUTINIB SHOWED IMPROVEMENTS IN ITCH AND HIVES AS EARLY AS WEEK 1, WITH BENEFITS SUSTAINED THROUGH WEEK 521. IMPROVEMENTS IN QUALITY OF LIFE AND SLEEP WERE ALSO OBSERVED EARLY IN TREATMENT 1. REMIBRUTINIB WAS WELL TOLERATED AND DEMONSTRATED A FAVORABLE SAFETY PROFILE, INCLUDING NO LIVER SAFETY CONCERNS ACROSS BOTH STUDIES THROUGH WEEK 521. PEOPLE LIVING WITH CSU OFTEN ENDURE YEARS OF FRUSTRATION, AND DIFFICULTY BEING TAKEN SERIOUSLY. FOR MANY, THE UNPREDICTABLE ITCH FLAREUPS CAN MAKE IT HARD TO SLEEP, FOCUS ON DAILY RESPONSIBILITIES, OR EVEN PERFORM THEIR JOBS AT TIMES, SAID TONYA WINDERS, PRESIDENT AND CEO, GLOBAL ALLERGY & AIRWAYS PATIENT PLATFORM (GAAPP). THE ARRIVAL OF A NEW ORAL TREATMENT OPTION BRINGS US ONE STEP CLOSER TO ENSURING THAT EVERY PERSON HAS THE OPPORTUNITY TO LIVE FULLY AGAIN. TODAY'S POSITIVE CHMP OPINION IS AN IMPORTANT STEP TOWARDS ADDRESSING THE SIGNIFICANT UNMET NEEDS OF ADULTS LIVING WITH CSU IN EUROPE, SAID PATRICK HORBER, M.D., PRESIDENT, INTERNATIONAL, NOVARTIS. WE WILL 

NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR REMIBRUTINIB IN CHRONIC SPONTANEOUS URTICARIA (CSU)

BASEL, FEBRUARY 23, 2026  NOVARTIS WILL PRESENT DATA FROM FIVE KEY ABSTRACTS EVALUATING THE HIGHLY SELECTIVE ORAL BRUTON'S TYROSINE KINASE INHIBITOR (BTKI) RHAPSIDO (REMIBRUTINIB) IN CHRONIC SPONTANEOUS URTICARIA (CSU) AND AS AN INVESTIGATIONAL THERAPY FOR PEANUT ALLERGY AT THE AMERICAN ACADEMY OF ALLERGY, ASTHMA & IMMUNOLOGY (AAAAI) ANNUAL MEETING IN PHILADELPHIA, PA, FROM FEBRUARY 27 TO MARCH 2, 2026. THESE PRESENTATIONS PROVIDE MORE EVIDENCE ON THE USE OF RHAPSIDO IN CSU, AS WELL AS ITS POTENTIAL IN OTHER INDICATIONS AND HIGHLIGHT NOVARTIS COMMITMENT TO ADDRESSING UNMET NEEDS IN PATIENTS WITH IMMUNE-MEDIATED DISEASES. NEW ANALYSES ON THE IMPACT OF RHAPSIDO ON DISEASE CONTROL AND EARLY SYMPTOM RELIEF FROM THE PHASE III REMIX-1 AND REMIX-2 TRIALS IN CSU WILL BE PRESENTED. ADDITIONALLY, THE FIRST PRESENTATION OF PHASE II FA DATA FOR REMIBRUTINIB, FOCUSING ON IGEMEDIATED PEANUT ALLERGY, WILL BE FEATURED IN AN ORAL SESSION. PLANS ARE IN PROGRESS TO BEGIN THE PHASE III PROGRAM IN FA IN 2026. THESE FOOD ALLERGY (FA) DATA FURTHER STRENGTHEN THE EVIDENCE SUPPORTING REMIBRUTINIB AS A NOVEL, WELL-TOLERATED, ORAL OPTION FOR PATIENTS WITH ALLERGIC AND IMMUNE-MEDIATED DISEASES, COMPLEMENTING THE RECENT FDA APPROVAL IN CHRONIC SPONTANEOUS URTICARIA (CSU) AND UNDERSCORING ITS BROADER THERAPEUTIC POTENTIAL, SAID ANGELIKA JAHREIS, GLOBAL HEAD, IMMUNOLOGY DEVELOPMENT, NOVARTIS. "OUR PRIORITY IS ADVANCING THERAPIES FOR PATIENTS WHO HAVE FEW ALTERNATIVES AND EXPANDING THE REACH OF INNOVATIVE MEDICINES TO TRANSFORM CARE ACROSS MULTIPLE, HIGH-NEED DISEASE AREAS." REGULATORY REVIEWS FOR REMIBRUTINIB FOR THE TREATMENT OF CSU ARE UNDERWAY IN SEVERAL REGIONS, INCLUDING THE EUROPEAN UNION AND JAPAN. IN ADDITION TO FA, REMIBRUTINIB IS IN CLINICAL DEVELOPMENT FOR CHRONIC INDUCIBLE URTICARIA (CINDU) AND HIDRADENITIS SUPPURATIVA (HS).FDA SUBMISSION FOR REMIBRUTINIB IN SYMPTOMATIC DERMOGRAPHISM, THE MOST PREVALENT TYPE OF CINDU, WAS COMPLETED IN Q4 2025. ADDITIONALLY, POSITIVE TOPLINE RESULTS WE

NOVARTIS PRESENTS RHAPSIDO (REMIBRUTINIB) DATA AT AAAAI, SHOWING POTENTIAL BEYOND CHRONIC SPONTANEOUS URTICARIA (CSU)

SANTA CRUZ, CALIF., FEB. 18, 2026 (GLOBE NEWSWIRE) -- UNNATURAL PRODUCTS, INC. (UNP), A BIOTECH DEVELOPING ORALLY-DELIVERED MACROCYCLIC PEPTIDES TO ADDRESS PREVIOUSLY UNDRUGGABLE TARGETS, TODAY ANNOUNCED A RESEARCH COLLABORATION AND LICENSING AGREEMENT WITH NOVARTIS ON AN UNDISCLOSED PROGRAM.

UNNATURAL PRODUCTS ANNOUNCES LICENSING AGREEMENT WITH NOVARTIS TO DEVELOP MACROCYCLIC PEPTIDE THERAPEUTICS

BASEL, FEBRUARY 18, 2026  NOVARTIS TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM ITS PIVOTAL PHASE III REMIND TRIAL OF ORAL REMIBRUTINIB IN CHRONIC INDUCIBLE URTICARIA (CINDU)1. THE PRIMARY ENDPOINT WAS MET FOR THE THREE MOST PREVALENT TYPES OF CINDU: SYMPTOMATIC DERMOGRAPHISM, COLD URTICARIA AND CHOLINERGIC URTICARIA, ACHIEVING SIGNIFICANTLY HIGHER COMPLETE RESPONSE RATES VERSUS PLACEBO AT WEEK 121. THESE DATA REPRESENT AN IMPORTANT ADVANCE IN THE TREATMENT OF CINDU, DEMONSTRATING THE POTENTIAL OF REMIBRUTINIB TO BE THE FIRST TARGETED THERAPY FOR CINDU AND ADDRESS A MAJOR UNMET NEED.

NOVARTIS REMIBRUTINIB FIRST THERAPY TO ACHIEVE PHASE III PRIMARY ENDPOINT IN CHRONIC INDUCIBLE URTICARIA (CINDU)

BASEL, FEBRUARY 13, 2026  NOVARTIS TODAY ANNOUNCED FINAL RESULTS FROM THE PHASE III ALIGN STUDY SUPPORTING A SLOWING DECLINE IN KIDNEY FUNCTION IN ADULTS WITH IGA NEPHROPATHY (IGAN) WHO WERE TREATED WITH VANRAFIA (ATRASENTAN). VANRAFIASHOWED A DIFFERENCE OF 2.39 ML/MIN/1.73M2 IN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) CHANGE FROM BASELINE VS. PLACEBO (2-SIDED P = 0.057) AT WEEK 136, 4 WEEKS AFTER THE END OF STUDY TREATMENT1. CLINICALLY MEANINGFUL RESULTS WERE OBSERVED WITH VANRAFIA COMPARED TO PLACEBO IN EGFR CHANGE FROM BASELINE AT THE END OF STUDY TREATMENT AT WEEK 132, AND IN THE PRESPECIFIED EXPLORATORY GROUP OF PATIENTS ADDITIONALLY RECEIVING SODIUM-GLUCOSE CO-TRANSPORTER-2 (SGLT2) INHIBITORS1. AT THE END OF TREATMENT AT WEEK 132, THE EGFR CHANGE FROM BASELINE COMPARED TO PLACEBO WAS 2.59 ML/MIN/1.73 M2 (NOMINAL 2- SIDED P = 0.039)1. PROGRESSIVE AND COMPLEX DISEASES SUCH AS IGAN PRESENT AN URGENT NEED FOR MEDICINES THAT CAN TARGET THE DIFFERENT DRIVERS OF THE DISEASE. VANRAFIA CAN BE SEAMLESSLY INTEGRATED INTO PATIENTS' EXISTING TREATMENT PLANS, WITH A CONSISTENT SAFETY PROFILE, SAID RUCHIRA GLASER, M.D., GLOBAL HEAD, CARDIOVASCULAR, RENAL & METABOLIC DEVELOPMENT UNIT, NOVARTIS. WE ARE PLEASED WITH TODAY'S PHASE III ALIGN RESULTS, WHICH ADD TO THE GROWING EVIDENCE OF VANRAFIA AS A POTENTIAL FOUNDATIONAL THERAPY TO SLOW KIDNEY FUNCTION DECLINE. ALIGN PROVIDES THE LONGEST FOLLOW-UP PERIOD IN PIVOTAL PHASE III STUDIES FOR IGAN3. SAFETY WAS CONSISTENT WITH PREVIOUS FINDINGS1. ALONGSIDE VANRAFIA, NOVARTIS CONTINUES TO ADVANCE ITS MULTI-ASSET IGAN PORTFOLIO, WHICH ALSO INCLUDES FABHALTA (IPTACOPAN) AND INVESTIGATIONAL COMPOUND ZIGAKIBART. ABOUT IGAN IGAN IS A PROGRESSIVE AUTOIMMUNE KIDNEY DISEASE WITH APPROXIMATELY 25 PER MILLION PEOPLE NEWLY DIAGNOSED WORLDWIDE EACH YEAR4. IGAN IS HIGHLY DEBILITATING AS IT LEADS TO GLOMERULAR INFLAMMATION (WHEN THE SMALL FILTERS IN THE KIDNEYS ARE INFLAMED), PROTEINURIA (EXCESS PROTEIN IN URINE), AND A GRADUAL DECLINE IN EGFR5. 

NOVARTIS VANRAFIA PHASE III DATA SUPPORT SLOWING OF KIDNEY FUNCTION DECLINE IN PATIENTS WITH IGA NEPHROPATHY

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR FULL YEAR NET SALES GREW +8% (CC 1 , +8% USD) WITH CORE OPERATING INCOME 1 UP +14% (CC, +12% USD) SALES GROWTH DRIVEN BY CONTINUED STRONG PERFORMANCE FROM PRIORITY BRANDS INCLUDING KISQALI (+57% CC), KESIMPTA (+36% CC), PLUVICTO (+42% CC), SCEMBLIX (+85% CC) AND COSENTYX (+8% CC) CORE OPERATING INCOME MARGIN1 WAS 40.1%, +210 BASIS POINTS (CC) OPERATING INCOME GREW +25% (CC, +21% USD); NET INCOME UP +19% (CC, +17% USD) CORE EPS 1 GREW +17% (CC, +15% USD) TO USD 8.98 FREE CASH FLOW 1 OF USD 17.6 BILLION (+8% USD) DRIVEN BY HIGHER NET CASH FLOWS FROM OPERATING ACTIVITIES FOURTH QUARTER NET SALES -1% (CC, +1% USD), IMPACTED BY US GENERIC EROSION AND REVENUE DEDUCTION ADJUSTMENTS; CORE OPERATING INCOME +1% (CC, +1% USD) PRIORITY BRANDS CONTINUED THEIR STRONG MOMENTUM INCLUDING KISQALI (+44% CC), KESIMPTA (+27% CC), PLUVICTO (+70% CC), SCEMBLIX (+87% CC) AND COSENTYX (+11% CC) Q4 SELECTED INNOVATION MILESTONES: REMIBRUTINIB FDA SUBMISSION FOR THE MOST COMMON SUBTYPE OF CINDU PELABRESIB POSITIVE PHASE III MANIFEST-2 96-WEEK DATA; FILING PLANNED IN EU, US PHASE III PLANNED ITVISMA FDA APPROVAL AS THE ONLY GENE REPLACEMENT THERAPY FOR A BROAD SMA POPULATION SCEMBLIX EC APPROVAL FOR NEWLY DIAGNOSED PATIENTS WITH PH+ CML IN CHRONIC PHASE PLUVICTO FDA SUBMISSION FOR PSMA+ METASTATIC HORMONE-SENSITIVE PROSTATE CANCER DIVIDEND , GUIDANCE DIVIDEND OF CHF 3.70 PER SHARE, AN INCREASE OF 5.7%, PROPOSED FOR 2025 2026 GUIDANCE 2  NET SALES EXPECTED TO GROW LOW SINGLE-DIGIT AND CORE OPERATING INCOME EXPECTED TO DECLINE LOW SINGLE-DIGIT BASEL, FEBRUARY 4, 2026  COMMENTING ON Q4 2025 RESULTS, VAS NARASIMHAN, CEO OF NOVARTIS, SAID: NOVARTIS DELIVERED STRONG PERFORMANCE IN 2025, WITH HIGH SINGLE-DIGIT SALES GROWTH AND CORE MARGIN EXPANSION DESPITE SIGNIFICANT US GENERIC ENTRIES.

Novartis AG

NVS

Price

Financial Reports

No items found.

Press Releases

Novartis AG

NVS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NVS